A Study of MK-7145 in Participants With Renal Insufficiency (Part I) and Heart Failure With Renal Insufficiency (Part II) (MK-7145-011)

Inclusion Criteria: Parts I and II

• If female, must be of non-child bearing potential or, if of child-bearing potentialagrees to use at least 2 acceptable contraceptive measures

• Body Mass Index (BMI) >=17.5 and <=38 kg/m^2

• No present history of clinically significant uncontrolled arrhythmias onelectrocardiogram (ECG)

• Nonsmoker or a light smoker consuming up to an average of 20 cigarettes (or equivalenttobacco product) per day. Part I Only

• Estimated creatinine clearance of ≤45 mL/min. Part II Only

• Class II or III heart failure as specified by the New York Heart Association (NYHA)functional classification for heart failure with NT-proBNP >=1000 pg/mL on clinicallyoptimized therapy with a stable dose (for at least 2 weeks) of furosemide or torsemide

• Estimated creatinine clearance of ≤45 mL/min

Exclusion Criteria: Parts I and II

• Mentally or legally institutionalized and/or incapacitated, has significant emotionalproblems or has a history of a clinically significant psychiatric disorder over thelast 5 years. This includes any mood disorder requiring concomitant use of lithium

• Diagnosed with acute coronary syndrome or acute cardiovascular (CV) event, or has beenhospitalized for HF exacerbation within less than 3 months of study entry

• Unstable angina pectoris

• Diabetes requiring high dose peroxisome proliferator-activated receptor (PPAR)antagonist (e.g. >30 mg of pioglitazone) or unstable insulin use

• Infectious disease requiring concomitant use of aminoglycosides

• Low plasma potassium (hypokalemia)

• Recent (within 6 months) history of stroke, uncontrolled seizures, or uncontrolledmajor neurological disorder

• Urinary retention, hydronephrosis or hydroureter

• Active nephrocalcinosis, nephrolithiasis, or hypercalciuria

• Functional disability that can interfere with rising from a semi-recumbent position tothe standing position

• History of malignant neoplastic disease

• Unable to refrain from the use of medication, including prescription andnon-prescription drugs such as high-dose aspirin (≥325 mg/day), non-steroidalanti-inflammatory drugs (NSAIDs), human immunodeficiency virus (HIV) proteaseinhibitors (ritonavir, indinavir, nelfinavir), macrolide antibiotics (erythromycin,telithromycin, clarithromycin), chloramphenicol, azole antifungals (fluconazole,ketoconazole, itraconazole, nefazodone, aprepitant, verapamil, diltiazem, etc.),anticonvulsants and mood stabilizers (e.g., phenytoin, carbamazepine, oxcarbazepine),barbiturates (phenobarbital), HIV non-nucleoside reverse transcriptase inhibitors (efavirenz, nevirapine, etravirine), rifampicin, modafinil, St John's wort,cyproterone (antiandrogen, progestin), etc. beginning approximately 2 weeks (or 5half-lives), prior to administration of the initial dose of study drug, throughout thestudy (including washout intervals between treatment periods) until the poststudyvisit

• Consumes excessive amounts of alcohol, defined as greater than 5 glasses of alcoholicbeverages (1 glass is approximately equivalent to: beer [284 mL/10 ounces], wine [125mL/4 ounces], or distilled spirits [25 mL/1 ounce]) per day

• Consumes excessive amounts, defined as greater than 6 servings (1 serving isapproximately equivalent to 120 mg of caffeine) of coffee, tea, cola, or othercaffeinated beverages per day

• Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) orparticipated in another investigational study within 4 weeks

• Regular user of any illicit drugs or has a history of drug (including alcohol) abusewithin approximately 6 months